Unity Biotechnology is a clinical-stage biotechnology company focused on developing therapeutics to slow, halt, or reverse diseases associated with aging. Their core approach targets senescent cells, which accumulate with age and contribute to various conditions like ophthalmologic and neurologic disorders. By aiming to eliminate these cells, Unity seeks to improve healthspan and address unmet medical needs in an aging global population. They are publicly traded on the NASDAQ under the ticker UBX.
The headquarters serves as the primary center for Unity's research and development activities, clinical operations, and corporate functions, driving its mission to create therapies for age-related diseases.
Situated in a region known for cutting-edge biotech facilities, the headquarters likely features advanced laboratory spaces, modern offices designed for collaboration, and infrastructure supporting complex scientific research.
The work culture at Unity Biotechnology's South San Francisco headquarters is characterized by a strong emphasis on scientific innovation, collaboration, and a shared commitment to addressing the challenges of aging. Employees are typically driven by a patient-centric mission within a dynamic and intellectually stimulating environment.
Unity's headquarters in South San Francisco is significant due to its proximity to a rich ecosystem of talent, research institutions, and venture capital, which is crucial for a biotech company advancing novel therapeutics.
While Unity Biotechnology is headquartered in the United States, its operations and collaborations extend globally. The company engages in clinical trials that may involve research sites and patient populations in various countries. Furthermore, its scientific partnerships, investor base, and the potential future commercialization of its therapies for age-related diseases inherently address a worldwide health concern, giving its mission a global scope.
285 East Grand Avenue
South San Francisco
CA
USA
Address: N/A
This centralized approach allows for efficient resource allocation, streamlined communication, and close collaboration among the company's various teams as they work towards their scientific and clinical goals.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Unity Biotechnology' leadership includes:
Unity Biotechnology has been backed by several prominent investors over the years, including:
Over the past 12 months, Unity Biotechnology has experienced notable leadership changes, including the appointment of a new Chief Financial Officer, a new Chief Medical Officer, and a new Chief Development Operations Officer, alongside the departure of the former Chief Medical Officer. These changes reflect a period of strategic team building as the company advances its clinical programs.
Discover the tools Unity Biotechnology uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Unity Biotechnology commonly uses the email format combining the first initial of an employee's first name with their full last name, followed by '@unitybiotechnology.com'. This is a prevalent structure in many biotech and tech companies.
[first_initial][last]@unitybiotechnology.com
Format
aghosh@unitybiotechnology.com
Example
75%
Success rate
GlobeNewswire • August 1, 2024
UNITY Biotechnology announced key additions to its leadership team: Stephen Somit, M.D., as Chief Medical Officer and Gilberto Sustache, PharmD, as Chief Development Operations Officer, effective August 1, 2024....more
GlobeNewswire • June 10, 2024
UNITY Biotechnology announced that positive 48-week data from its Phase 2 BEHOLD study of UBX1325 in patients with diabetic macular edema (DME) were presented at the Clinical Trials at the Summit (CTS) meeting....more
GlobeNewswire • February 6, 2024
UNITY Biotechnology announced the appointment of Prithvi Ram trasp as its new Chief Financial Officer, effective February 5, 2024. Mr. Ram trasp brings over two decades of experience in finance and corporate strategy within the biopharmaceutical industry....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Unity Biotechnology, are just a search away.